Abigail Liebow

1.7k total citations · 1 hit paper
13 papers, 1.3k citations indexed

About

Abigail Liebow is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Abigail Liebow has authored 13 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Abigail Liebow's work include RNA Interference and Gene Delivery (6 papers), Porphyrin Metabolism and Disorders (4 papers) and Kidney Stones and Urolithiasis Treatments (3 papers). Abigail Liebow is often cited by papers focused on RNA Interference and Gene Delivery (6 papers), Porphyrin Metabolism and Disorders (4 papers) and Kidney Stones and Urolithiasis Treatments (3 papers). Abigail Liebow collaborates with scholars based in United States, United Kingdom and Australia. Abigail Liebow's co-authors include Kevin Fitzgerald, William Querbes, Brian R. Bettencourt, Svetlana Shulga‐Morskaya, Amy Simon, Stuart Milstein, Klaus Charissé, Martin A. Maier, Jay D. Horton and Jessica E. Sutherland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Circulation.

In The Last Decade

Abigail Liebow

13 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

2013 467 citations Kevin Fitzgerald, Maria Frank-Kamenetsky et al. The Lancet profile →

Peers

Countries citing papers authored by Abigail Liebow

Since Specialization

Citations

This map shows the geographic impact of Abigail Liebow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abigail Liebow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abigail Liebow more than expected).

Fields of papers citing papers by Abigail Liebow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abigail Liebow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abigail Liebow. The network helps show where Abigail Liebow may publish in the future.

Co-authorship network of co-authors of Abigail Liebow

This figure shows the co-authorship network connecting the top 25 collaborators of Abigail Liebow. A scholar is included among the top collaborators of Abigail Liebow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abigail Liebow. Abigail Liebow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus 2020 ·Journal of Hepatology ·Yesseinia Angleró-Rodríguez, Florian A. Lempp, Abigail Liebow, Nguyen Van Tuyen, (unknown), Charalambos Kaittanis, (unknown), Adam Castoreno, (unknown), Hannah Kaiser, (unknown), Stuart Milstein, Vasant Jadhav, Anna I. Bakardjiev	2
2	Improving Drug Discovery by Nucleic Acid Delivery in Engineered Human Microlivers 2019 ·Cell Metabolism ·Liliana Mâncio-Silva, Heather E. Fleming, A. B. Miller, Stuart Milstein, Abigail Liebow, Patrick Haslett, Laura Sepp‐Lorenzino, (unknown)	10
3	Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity 2019 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Kyle D. Wood, Ross P. Holmes, David V. Erbe, Abigail Liebow, Sonia Fargue, John Knight	36
4	Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol 2017 ·Atherosclerosis ·Yuxin Xu, (unknown), Haojie Yu, William Querbes, James P. Pirruccello, Abigail Liebow, Amy Deik, Kevin Trindade, Xiao Wang, Kiran Musunuru, Clary B. Clish, Chad A. Cowan, (unknown), Daniel J. Rader, Sekar Kathiresan	87
5	An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria 2016 ·Journal of the American Society of Nephrology ·Abigail Liebow, Xingsheng Li, Timothy Racie, Julia Hettinger, Brian R. Bettencourt, Nader Najafian, Patrick Haslett, Kevin Fitzgerald, Ross P. Holmes, David V. Erbe, William Querbes, John Knight	159
6	Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent N‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo 2015 ·ChemBioChem ·Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Muthusamy Jayaraman, Klaus Charissé, Nate Taneja, Jonathan O′Shea, Jennifer L. S. Willoughby, Kristina Yucius, Tuyen Nguyen, Svetlana Shulga‐Morskaya, Stuart Milstein, Abigail Liebow, William Querbes, Anna Borodovsky, Kevin Fitzgerald, Martin A. Maier, Muthiah Manoharan	148
7	Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification 2015 ·Molecular Therapy — Nucleic Acids ·Amy Chan, Abigail Liebow, Makiko Yasuda, Lin Gan, Tim Racie, Martin A. Maier, Satya Kuchimanchi, Don Foster, Stuart Milstein, Klaus Charissé, Alfica Sehgal, Muthiah Manoharan, Rachel Meyers, Kevin Fitzgerald, Amy Simon, Robert J. Desnick, William Querbes	108
8	Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase 2015 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Xingsheng Li, John Knight, Sonia Fargue, (unknown), Zhengrong Guan, Edward W. Inscho, Abigail Liebow, Kevin Fitzgerald, William Querbes, W. Todd Lowther, Ross P. Holmes	29
9	siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes 2015 ·ACS Chemical Biology ·Shigeo Matsuda, (unknown), Jayaprakash K. Nair, Klaus Charissé, Rajar M. Manoharan, Philip Kretschmer, Chang G. Peng, Alexander V. Kel’in, Kandasamy Pachamuthu, Jennifer L. S. Willoughby, Abigail Liebow, William Querbes, Kristina Yucius, Tuyen Nguyen, Stuart Milstein, Martin A. Maier, Kallanthottathil G. Rajeev, Muthiah Manoharan	167
10	Abstract 11936: Development of Monthly to Quarterly Subcutaneous Administration of RNAi Therapeutics Targeting the Metabolic Diseases Genes PCSK9, ApoC3 and ANGPTL3 2014 ·Circulation ·Anna Borodovsky, William Querbes, Jessica E. Sutherland, Renta Hutabarat, Stuart Milstein, Satya Kuchimanchi, (unknown), Klaus Charissé, Kristina Yucius, Abigail Liebow, Andrew Sprague, Martin A. Maier, David Kallend, Amy Simon, Jay D. Horton, Kevin Fitzgerald	4
11	Abstract 7: A Subcutaneous, Potent and Durable RNAi Platform Targeting Metabolic Diseases, Genes PCSK9, ApoC3 and ANGPLT3 2014 ·Arteriosclerosis Thrombosis and Vascular Biology ·Kevin Fitzgerald, Anna Borodovsky, William Querbes, Jessica E. Sutherland, Renta Hutabarat, Stuart Milstein, Satya Kuchimanchi, (unknown), Klaus Charissé, (unknown), Abigail Liebow, Andrew Sprague, Martin A. Maier, David Kallend, Jay D. Horton, Amy Simon	7
12	RNAi-mediated silencing of hepaticAlas1effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice 2014 ·Proceedings of the National Academy of Sciences ·Makiko Yasuda, Lin Gan, Brenden Chen, (unknown), Chunli Yu, John D. Phillips, Maria I. New, Abigail Liebow, Kevin Fitzgerald, William Querbes, Robert J. Desnick	98
13	Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial breakdown → 2013 ·The Lancet ·Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, Abigail Liebow, Brian R. Bettencourt, Jessica E. Sutherland, Renta Hutabarat, Valerie A. Clausen, Verena Karsten, Jeffrey Cehelsky, Saraswathy V. Nochur, Victor Kotelianski, Jay D. Horton, Timothy Mant, Joseph Chiesa, James M. Ritter, (unknown), Akshay Vaishnaw, Jared Gollob, Amy Simon	467

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact